Close Menu

NEW YORK – Myriad Genetics announced on Wednesday morning that it is withdrawing its fiscal year 2020 financial guidance due to the impact of the COVID-19 pandemic.

Before mid-March, Myriad was experiencing test volume trends in line with its expectations, but starting late March and into its fiscal fourth quarter, social distancing guidelines began significantly impacting test volume trends, according to Bryan Riggsbee, the company's interim CEO and CFO. He didn't provide any further details on the magnitude of the impact.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.